Graybug Vision Inc. (GRAY)

[Da Ghost]

weeeeeeeee thanks $GRAY

[interloper]

Yeah it is, big time.

[TruckingAngler]

GRAY tearing up after-hours!!

[DR. EVIL]

Did everyone get my alert??

BAWHAHAHA

[TruckingAngler]

Yes GRAY

[Da Ghost]

GRAY


Looking decent -

[Frankestin]

someone covers ... I don't sell!
So undervalue

[TruckingAngler]

GRAY looking great again on no news.
Maybe inside leak?
GLTA

[georgie18]

GRAY...$4.49...Psar flipped to a Bullish buy Position on strong volume spike yesterday...

georgie18 Thursday, 05/27/21 06:48:56 AM
Re: None 0
Post #
14
of 17
GRAY...$3.71...Bullish Engulfing Reversal Pattern to the Upside on this Oversold Chart...

Open Gap in the $14 range...Taking a starter here and will add accordingly...up or down...

Chart...https://schrts.co/JcuDkCwH ...

As of March 31, 2021, the company’s cash, cash equivalents, and short-term investments totaled $85.7 million, compared to $95.0 million as of December 31, 2020. The decrease was primarily due to the loss from operations of $11.5 million. The company’s current cash and investments are sufficient to support its currently planned operations into the first half of 2023.

[georgie18]

We shall see...

[TruckingAngler]

GRAY heading back to March's $7s or $30s of February?
GLTA
..
..

[georgie18]

GRAY...$3.90...in the P/M...

[georgie18]

GRAY...$3.71...Bullish Engulfing Reversal Pattern to the Upside on this Oversold Chart...

Open Gap in the $14 range...Taking a starter here and will add accordingly...up or down...

Chart...https://schrts.co/JcuDkCwH ...

As of March 31, 2021, the company’s cash, cash equivalents, and short-term investments totaled $85.7 million, compared to $95.0 million as of December 31, 2020. The decrease was primarily due to the loss from operations of $11.5 million. The company’s current cash and investments are sufficient to support its currently planned operations into the first half of 2023.

[TruckingAngler]

GRAY nice move again !

[TruckingAngler]

GRAY finally on way back UP....
GRAY's worst in 12mo was $12 so looking good form here...
GLTA

[Frankestin]

Gray has about 90 million cash and MC is at 110
I'll take some!

[TruckingAngler]

GRAY low volume take down

[Grandmasim]

IMVHO------Very soon this should have a VERY nice pop!

[hutchpiece]

TOTALLY MY FAULT!!!! I didnt see GRAY 3/9/21... I saw the 9th. Today is the 9th. I would hope this comes back strong.

[TruckingAngler]

GRAY's pipeline shows to be UP from here...
Strong pipe-line.
I don't see any update since the March 09?

[hutchpiece]

I got this from graybugs site.... sounds like decent news.
https://investors.graybug.vision/

[TruckingAngler]

GRAY has RSI screaming BUY. Has to be short manipulation today.
Should cause big move within next 2 weeks..
GLTA
.
.
....

[TruckingAngler]

Why the GRAY "dip" ?
GRAY is a $15 potential prior to confirmed data, and then $27++..IMO..

"Graybug Vision Inc (NASDAQ: GRAY) shares are dropped after preliminary data from Phase 2b ALTISSIMO trial of GB-102 for wet age-related macular degeneration (wet AMD).

Investors are reacting to the mean change of best-corrected visual acuity (BCVA) from the baseline that was lower in GB-102 1mg than aflibercept arm.
The mean change from baseline for BCVA for all 20 completers was approximately nine letters lower across all time points versus the study control arm.
The study was designed to evaluate two separate doses of GB-102, 1mg, and 2mg, injected every six months compared with Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Eylea (aflibercept) injected every two months.
After interim safety analysis, the 2mg dose was discontinued after the initial dose, and all patients were switched to 1mg for their second dose.
The median time to first supportive therapy was five months for GB-102 1mg (primary endpoint of the study).
Central subfield thickness of the retina in the GB-102 1mg arm was consistent with the study control arm.
GB-102, the company's lead product candidate, is a microparticle depot formulation of sunitinib malate, injected intravitreally.
Sunitinib is marketed as Sutent by Pfizer Inc (NYSE: PFE).
Piper Sandler has downgraded GRAY to Neutral with a price target of $10 from $27 earlier."

GLTA
.
.

[TruckingAngler]

GRAY: Possitive results likely to continue...
"Graybug Vision Reports Prelim. Topline Results From Phase 2b ALTISSIMO Trial; Median Time For First Supportive Therapy Was 5 Months For GB-102 1mg, 48% Of Patients In GB-102 1mg Arm Were Rescue-Free For At least Six Months
7:42 am ET March 9, 2021 (Benzinga) Print
Median time to first supportive therapy was 5 months for GB-102 1mg

48% of patients in the GB-102 1 mg arm were rescue-free for at least 6 months
Control of retinal thickness was consistent across all trial arms
Mean best-corrected visual acuity with GB-102 1mg trended lower than aflibercept arm
No drug-related serious adverse events
Clinical monitoring is ongoing to observe durability beyond 6 months
REDWOOD CITY, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today provided preliminary topline data from the 12-month treatment phase of its Phase 2b ALTISSIMO trial of GB-102 for the treatment of wet age-related macular degeneration (wet AMD), Graybug's proprietary microparticle depot formulation of sunitinib malate injected intravitreally.

The ALTISSIMO trial is a masked and controlled Phase 2b dose-ranging study of two doses of GB-102 with a single control arm of patients on aflibercept, conducted across 33 study sites in the United States. The primary endpoint is median time to first supportive therapy with a vascular endothelial growth factor (VEGF) inhibitor, and secondary endpoints are pharmacodynamics measures of mean change of best-corrected visual acuity (BCVA) from baseline and mean change of central subfield thickness (CST) of the retina from baseline.

The trial was originally designed to evaluate two separate doses of GB-102, 1mg and 2mg, injected every 6 months as compared with aflibercept injected every 2 months. Based on the results of an interim safety analysis, the 2mg dose was discontinued after the initial dose, and all patients in that arm were switched to 1mg for their second dose.

Analysis of the ALTISSIMO 1mg arm shows the primary endpoint of median time to first supportive therapy was 5 months. Furthermore, 48% of patients did not require supportive therapy for at least 6 months, and 62% of patients for at least 4 months or more, at least once during the trial. Overall, the 1mg dose performed better than the 2mg dose.

Overall, GB-102 1mg was well-tolerated. There were no drug-related serious adverse events, and the majority of drug-related adverse events were mild to moderate. Medication was detected in the anterior chamber in less than 10% of GB-102 1mg injections, and no adverse event required surgical intervention. There was no vision-threatening inflammation observed, and there was no increase in intraocular pressure reported.

CST and BCVA were measured as secondary endpoints. CST in the GB-102 1mg arm was consistent with the study control arm. The mean change from baseline for BCVA for all 20 completers was approximately 9 letters lower across all time points, on average, than that observed in the study control arm."

GLTA
.

.

[TruckingAngler]

GRAY's Fred Guerard named in Top 25 BioTech CEOs 2021...

24. Frederic Guerard - Company: Graybug Vision - Title: Chief Executive Officer.

"Frederic Guerard is the Chief Executive Officer of Graybug Vision, a company that develops transformative medicines for ocular diseases of the retina and optic nerve. Headquartered in Redwood City, California, Graybug's proprietary ocular delivery technologies are designed to maintain effective drug levels in ocular tissue for six months and potentially longer, improving disease management, reducing healthcare burdens, and ultimately delivering better clinical outcomes for patients with vision-threatening diseases, such as wet age-related macular degeneration.

Guerard has served as CEO of Graybug since 2019 and led the planning and successful execution of the company's IPO in September 2020. With over two decades of experience in the pharmaceutical industry, Guerard helped Graybug raise over $150 million between Series C funding and its IPO. Prior to Graybug, Guerard spent twenty years of his career at Novartis, where he most recently held the position of Worldwide Business Franchise Head Ophthalmology, among numerous leadership roles in the company. He also served on the Board of the Association of the British Pharmaceutical Industry and on the Board of Medicines Australia. Guerard holds a Doctorate of Pharmacy and a Master of Biological and Medical Sciences degree from the University of Rouen, France, as well as a Master of Marketing degree from the international business school HEC, Paris."

GLTA
.
.

[TruckingAngler]

GRAY "preliminary" wasn't a death blow.
It was an opportunity IMO...
It was ust the 1st step to more trials.
I'm ADDing at these levels...
GLTA